The Beauty Health Company
SKIN
$1.29
-$0.01-0.77%
| Weiss Ratings | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.00 | |||
| Price History | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -10.42% | |||
| 30-Day Total Return | -25.43% | |||
| 60-Day Total Return | -14.00% | |||
| 90-Day Total Return | -21.82% | |||
| Year to Date Total Return | -19.88% | |||
| 1-Year Total Return | -64.17% | |||
| 2-Year Total Return | -89.19% | |||
| 3-Year Total Return | -92.69% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -74.85% | |||
| 52-Week Low % Change | 42.86% | |||
| Price | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $5.17 | |||
| 52-Week Low Price | $0.91 | |||
| 52-Week Low Price (Date) | Aug 09, 2024 | |||
| 52-Week High Price (Date) | Mar 13, 2024 | |||
| Valuation | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 161.36M | |||
| Enterprise Value | 370.80M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.42 | |||
| Earnings Per Share Growth | -38.59% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.46 | |||
| Price/Book (Q) | 2.70 | |||
| Enterprise Value/Revenue (TTM) | 1.07 | |||
| Price | $1.29 | |||
| Enterprise Value/EBITDA (TTM) | -8.85 | |||
| Enterprise Value/EBIT | -4.70 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 124.06M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 800 603 4996 | |||
| Address | 2165 Spring Street Long Beach, CA 90806 | |||
| Website | www.beautyhealth.com | |||
| Country | United States | |||
| Year Founded | 1997 | |||
| Profitability | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -22.71% | |||
| Profit Margin | -8.10% | |||
| Management Effectiveness | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -5.90% | |||
| Return on Equity | -- | |||
| Income Statement | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 347.62M | |||
| Total Revenue (TTM) | 347.62M | |||
| Revenue Per Share | $2.80 | |||
| Gross Profit (TTM) | 175.64M | |||
| EBITDA (TTM) | -41.88M | |||
| EBIT (TTM) | -78.98M | |||
| Net Income (TTM) | -28.17M | |||
| Net Income Avl. to Common (TTM) | -28.17M | |||
| Total Revenue Growth (Q YOY) | -19.11% | |||
| Earnings Growth (Q YOY) | 75.22% | |||
| EPS Diluted (TTM) | -0.42 | |||
| EPS Diluted Growth (Q YOY) | 73.21% | |||
| Balance Sheet | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 358.89M | |||
| Cash Per Share (Q) | $2.89 | |||
| Total Current Assets (Q) | 485.05M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 59.72M | |||
| Current Ratio (Q) | 6.559 | |||
| Book Value Per Share (Q) | $0.48 | |||
| Total Assets (Q) | 699.55M | |||
| Total Current Liabilities (Q) | 73.95M | |||
| Total Debt (Q) | 568.33M | |||
| Total Liabilities (Q) | 639.82M | |||
| Total Common Equity (Q) | 59.72M | |||
| Cash Flow | SKIN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -8.10M | |||
| Cash from Financing (TTM) | -188.93M | |||
| Net Change in Cash (TTM) | -200.55M | |||
| Levered Free Cash Flow (TTM) | -375.60K | |||
| Cash from Operations (TTM) | -5.51M | |||
